logo

For the Inventor, By the Inventor

Scotch Plains, NJ, United States of America

Sobhana Babu Boga

This inventor holds 12 USPTO granted patents and 12 published patent applications and 13 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Merck Sharp + Dohme B.v.. Active years: 2013-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sobhana Babu Boga. Retrieved from https://idiyas.com/inventor/sobhana-babu-boga

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 

% Patents Active = 100.0

 

Average Co-Inventor Count = 14.2

ph-index = 2

Forward Citations = 17(Granted Patents)


Location History:

  • Kenilworth, NJ (US) (2014)
  • Scotch Plains, NJ (US) (2013 - 2019)
  • Karnataka, IN (2022)

Company Filing History:

goldMedal12 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal1 out of 55 
 
Merck Sharp + Dohme B.v.
 patents
where one patent can have more than one assignee

Years Active: 2013-2022

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 11427616 - PCSK9 antagonist compounds (2022-08-30),
2. 10246457 - Indazole and azaindazole Btk inhibitors (2019-04-02),
3. 10214546 - Btk inhibitors (2019-02-26),
4. 10208047 - Tertiary alcohol imidazopyrazine BTK inhibitors (2019-02-19),
5. 10130630 - BTK inhibitors (2018-11-20),
6. 10087188 - Benzamide imidazopyrazine Btk inhibitors (2018-10-02),
7. 9718828 - BTK Inhibitors (2017-08-01),
8. 9481682 - Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors (2016-11-01),
9. 8999966 - Compounds that are ERK inhibitors (2015-04-07),
10. 8999957 - Heterocyclic compounds as ERK inhibitors (2015-04-07),
11. 8716483 - Compounds that are ERK inhibitors (2014-05-06),
12. 8546404 - Compounds that are ERK inhibitors (2013-10-01),

Title: Unveiling the Inventive Journey of Sobhana Babu Boga

Introduction:

Sobhana Babu Boga, a distinguished inventor based in Scotch Plains, NJ, has left an indelible mark in the field of pharmaceutical innovation. With 12 patents to his name and a focus on developing cutting-edge compounds, Boga's contributions have significantly impacted the landscape of cardiovascular disease treatment and Btk-mediated disorders.

Latest Patents:

1. PCSK9 Antagonist Compounds: Boga's inventive work includes compounds aimed at antagonizing PCSK9, thereby offering promise in the treatment of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, and coronary heart disease.

2. Indazole and Azaindazole Btk Inhibitors: Boga's pioneering research extends to developing Btk inhibitor compounds for addressing Btk-mediated disorders, showcasing his commitment to therapeutic advancements in this domain.

Career Highlights:

Having collaborated with esteemed organizations like Merck Sharp & Dohme Corporation and Merck Sharp & Dohme B.V., Boga has honed his skills and expertise in the pharmaceutical industry. His groundbreaking patents underscore his dedication to pushing the boundaries of scientific innovation.

Collaborations:

Throughout his career, Boga has worked alongside notable peers such as Xiaolei Gao and Jian Liu. These collaborations have not only fostered a spirit of innovation but have also led to the successful development of novel compounds with significant therapeutic potential.

Conclusion:

Sobhana Babu Boga's inventive spirit and relentless pursuit of scientific excellence have solidified his position as a trailblazer in the realm of pharmaceutical innovation. His patents stand as a testament to his unwavering commitment to improving healthcare outcomes and advancing the frontiers of medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…